Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2017 1
2018 2
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Laryngeal Squamous Cell Carcinoma"
Page 1
Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
Guidi A, Codecà C, Ferrari D. Guidi A, et al. Med Oncol. 2018 Feb 13;35(3):37. doi: 10.1007/s12032-018-1096-5. Med Oncol. 2018. PMID: 29441454 Review.
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, the EXTREME regimen is the standard of care for the first-line treatment of recurrent/metastatic head and neck carcinoma …
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. ...Nowadays, …
Current studies of immunotherapy in head and neck cancer.
Dogan V, Rieckmann T, Münscher A, Busch CJ. Dogan V, et al. Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29. Clin Otolaryngol. 2018. PMID: 28464441 Review.
OBJECTIVE OF REVIEW: This review summarises current clinical studies using immune checkpoint modulators for the treatment of head and neck cancer (HNSCC). TYPE OF REVIEW: Systematic review. ...Therefore, pembrolizumab was granted accelerated approval for the treatme …
OBJECTIVE OF REVIEW: This review summarises current clinical studies using immune checkpoint modulators for the treatment of head and …
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O'Leary B, Braña I, Harrington KJ. Jiménez-Labaig P, et al. Cancer Treat Rev. 2024 Jul;128:102772. doi: 10.1016/j.ctrv.2024.102772. Epub 2024 May 26. Cancer Treat Rev. 2024. PMID: 38820656
INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. ...There were 13 A …
INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma …
Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J. Murdoch D, et al. Curr Opin Oncol. 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. Curr Opin Oncol. 2008. PMID: 18043264 Review.
(c) Colorectal cancer (CRC) - An overview of three RCTs in metastatic CRC revealed that bevacizumab plus 5-fluorouracil/leucovorin possesses a significant survival advantage over 5-fluorouracil/leucovorin and irinotecan/5-fluorouracil/leucovorin.(d) Non-small-cell lung can …
(c) Colorectal cancer (CRC) - An overview of three RCTs in metastatic CRC revealed that bevacizumab plus 5-fluorouracil/leucovorin possesses …
Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhu P, Wang Y, Zhang W, Liu X. Zhu P, et al. Medicine (Baltimore). 2021 Jan 29;100(4):e24339. doi: 10.1097/MD.0000000000024339. Medicine (Baltimore). 2021. PMID: 33530227 Free PMC article.
BACKGROUND: In recent years, a number of clinical trials for antibody drugs targeting programmed cell death protein 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1) have been carried out on recurrent or metastatic head and neck squamous cell …
BACKGROUND: In recent years, a number of clinical trials for antibody drugs targeting programmed cell death protein 1 (PD1)/programme …